1 active not recruiting, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow Kidney Neoplasm: new trials by email Literature Review of Kidney Neoplasm trials Research Report on Kidney Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC Casdatifan, Zimberelimab - Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2026-03-09 | 2026-03-20 |
| Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma Medication (A specification is listed under each arm), Patient reported outcomes measurement - Metastatic Renal Cell Carcinoma, Kidney Neoplasm | Phase 2 | Unknown | Herlev and Gentofte Hospital | 30 | 2020-03-06 | 2020-11-25 |
| Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors Hyperpolarized Carbon C 13 Pyruvate, Magnetic Resonance Imaging, Hyperpolarized 13C,15N2-urea - Benign Kidney Neoplasm, Kidney Neoplasm | Phase 2 | Active not recruiting | Zhen Wang, MD | 54 | 2019-01-15 | 2026-02-23 |
| [18F]Fluciclatide PET Imaging of Pazopanib Response 18F-Fluciclatide - Kidney Neoplasm | Phase 2 | Terminated | Asan Medical Center | 12 | 2013-09-01 | 2016-03-01 |
Kidney Neoplasms (4) · Carcinoma, Renal Cell (3) · Urogenital Neoplasms (1) · Urologic Neoplasms (1)
Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Adenocarcinoma (3) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Urogenital Neoplasms (3) · Urologic Neoplasms (3)
AH 111585 (1) · Dosage Forms (1) · Magnetic Resonance Spectroscopy (1) · zimberelimab (1)
Asan Medical Center (1) · Dana-Farber Cancer Institute (1) · Herlev and Gentofte Hospital (1) · Zhen Wang, MD (1)
United States (2) · Denmark (1) · South Korea (1)
Ida Marie L Rasmussen, MD (1) · Jin-Sook Ryu, MD. PhD. (1) · Wenxin Xu, MD (1) · Zhen Jane Wang, MD (1)
2019 (1), R01CA249909 (1)